関連する実験動画
Updated: Sep 9, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
6.0K
1型糖尿病におけるレクリエーションダイビング中の継続的なグルコースモニタリング:臨床的および技術的な不確実性を把握する
Djordje S Popovic1, Theocharis Koufakis2, Dimitrios Patoulias2
1Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia.
Diabetes, metabolic syndrome and obesity : targets and therapy
|September 3, 2025
まとめ
1型糖尿病の人はダイビングできますが,注意が必要です. 継続的なグルコースモニタリング (CGM) 装置は,糖尿病のダイバーで水中での使用の正確性がまだ証明されていません.
科学分野:
- 糖尿病について
- ダイビング 医学
- 医療技術
背景:
- レクリエーションダイビングは世界的に人気が高まっている.
- 歴史的に,糖尿病,特にインスリン治療は,ダイビングの禁忌でした.
- 現在のデータは,糖尿病が重要な併発性疾患のないダイバーにとって相対的な禁忌であることを示唆しています.
研究 の 目的:
- ダイビングする1型糖尿病 (PLT1D) 患者に対する継続的なグルコースモニタリング (CGM) 装置の精度,耐久性,水中性能に関する現在のデータをレビューする.
- PLT1Dダイバーの低血糖と高血糖のリスクを強調する
- 水中での使用のための信頼性の高いCGM技術に関するさらなる研究を要求する.
主な方法:
- 水中のCGM装置の性能に関する既存の観測データと文献のレビュー
- リアルタイムCGMシステムの精度と耐久性の分析
- 低血糖症の症状とダイビングに関連する要因の混同の可能性の評価
主要な成果:
- 低血糖はPLT1Dダイバーの主要な懸念であり,症状は潜水に関連する問題を模倣する可能性があります.
- 重度の高血糖症も最小限に抑える必要があります.
- 現在のリアルタイムCGMシステムは 水中での正確な使用の基準を満たしていないので 極めて注意が必要です
結論:
- PLT1Dのダイビングは可能ですが,現在のCGM技術は水中安全のために大幅な改善と検証を必要としています.
- PLT1DダイバーのCGMを広く採用する前に,さらなる大規模な試験が不可欠です.
- CGMの精度と信頼性の向上は,レクリエーションダイビングに参加する糖尿病患者の安全にとって不可欠です.
関連する概念動画
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Diabetes: Symptoms, Diagnosis, and Complications
685
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
685
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253

